Acurx Pharmaceuticals (NASDAQ: ACXP)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.330 | -0.260 | 0.0700 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Aeglea BioTherapeutics (NASDAQ:AGLE), Virios Therapeutics (NASDAQ:VIRI), Synaptogenix (NASDAQ:SNPX), Celyad Oncology (NASDAQ:CYAD) and Brooklyn (NASDAQ:BTX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by Maxim Group on Monday, November 29, 2021. The analyst firm set a price target for 12.00 expecting ACXP to rise to within 12 months (a possible 225.20% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $3.69 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.